FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200322352> ?p ?o ?g. }

• W4200322352 abstract "Background Oral anticoagulants may improve the survival of people with cancer through an antithrombotic effect, yet increase the risk of bleeding. Objectives To evaluate the efficacy and safety of oral anticoagulants in ambulatory people with cancer undergoing chemotherapy, targeted therapy, immunotherapy, or radiotherapy (either alone or in combination), with no standard therapeutic or prophylactic indication for anticoagulation. Search methods We conducted comprehensive searches on 14 June 2021, following the original electronic searches performed in February 2016 (last major search). We electronically searched the following databases: CENTRAL, MEDLINE, Embase. In addition, we handsearched conference proceedings, checked references of included studies, and searched for ongoing studies. As part of the living systematic review approach, we are running continual searches and will incorporate new evidence rapidly after it is identified. Selection criteria We included randomised controlled trials (RCTs) assessing the benefits and harms of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) in ambulatory people with cancer (i.e., not hospital inpatients during the time of their participation in trials) These people are typically undergoing systemic anticancer therapy, possibly including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, but otherwise have no standard therapeutic or prophylactic indication for anticoagulation. Data collection and analysis Using a standardised form, two review authors independently extracted data on study design, participants, intervention outcomes of interest, and risk of bias. Outcomes of interest included all‐cause mortality, pulmonary embolism, symptomatic deep vein thrombosis (DVT), major bleeding, minor bleeding and health‐related quality of life. We assessed the certainty of evidence for each outcome using the GRADE approach. Main results Of 12,620 identified citations, 10 RCTs fulfilled the inclusion criteria. The oral anticoagulant was a vitamin K antagonist (VKA) in six of these RCTs, and a direct oral anticoagulant (DOAC) in the remaining four RCTs (three studies used apixaban; one used rivaroxaban). The comparator was either placebo or no prophylaxis. Compared to no prophylaxis, vitamin K antagonists (VKAs) probably reduce mortality at six months slightly (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.77 to 1.13; risk difference (RD) 22 fewer per 1000, 95% CI 72 fewer to 41 more; moderate‐certainty evidence), and probably reduce mortality at 12 months slightly (RR 0.95, 95% CI 0.87 to 1.03; RD 29 fewer per 1000, 95% CI 75 fewer to 17 more; moderate‐certainty evidence). One study assessed the effect of a VKA compared to no prophylaxis on thrombosis; the evidence was very uncertain about the effect of VKA compared to no VKA on pulmonary embolism and symptomatic DVT (RR 1.05, 95% CI 0.07 to 16.58; RD 0 fewer per 1000, 95% CI 6 fewer to 98 more; very low‐certainty evidence; RR 0.08, 95% CI 0.01 to 1.42; RD 35 fewer per 1000, 95% CI 37 fewer to 16 more; very low‐certainty evidence, respectively). Also, VKAs probably increase major and minor bleeding at 12 months (RR 2.93, 95% CI 1.86 to 4.62; RD 107 more per 1000, 95% CI 48 more to 201 more; moderate‐certainty evidence for major bleeding, and RR 3.14, 95% CI 1.85 to 5.32; RD 167 more per 1000, 95% CI 66 more to 337 more; moderate‐certainty evidence for minor bleeding). Compared to no prophylaxis, at three to six months, direct oral anticoagulants (DOACs) probably reduce mortality slightly (RR 0.94, 95% CI 0.64 to 1.38, RD 11 fewer per 1000, 95% CI 67 fewer to 70 more; moderate‐certainty evidence), probably reduce the risk of pulmonary embolism slightly compared to no prophylaxis (RR 0.48, 95% CI 0.24 to 0.98; RD 24 fewer per 1000, 95% CI 35 fewer to 1 fewer; moderate‐certainty evidence), probably reduce symptomatic DVT slightly (RR 0.58, 95% CI 0.30 to 1.15; RD 21 fewer per 1000, 95% CI 35 fewer to 8 more; moderate‐certainty evidence), probably do not increase major bleeding (RR 1.65, 95% CI 0.72 to 3.80; RD 9 more per 1000, 95% CI 4 fewer to 40 more; moderate‐certainty evidence), and may increase minor bleeding (RR 3.58, 95% CI 0.55 to 23.44; RD 55 more per 1000, 95% CI 10 fewer to 482 more; low‐certainty evidence). Authors' conclusions In ambulatory people with cancer undergoing chemotherapy, targeted therapy, immunotherapy, or radiotherapy (either alone or in combination), the current evidence on VKA thromboprophylaxis suggests that the harm of major bleeding might outweigh the benefit of reduction in venous thromboembolism. With DOACs, the benefit of reduction in venous thromboembolic events outweighs the risk of major bleeding. Editorial note: this is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence, as it becomes available. Please refer to the 'What's new' section in the Cochrane Database of Systematic Reviews for the current status of this review." @default.
• W4200322352 created "2021-12-31" @default.
• W4200322352 creator A5013491140 @default.
• W4200322352 creator A5024459640 @default.
• W4200322352 creator A5026324699 @default.
• W4200322352 creator A5041615321 @default.
• W4200322352 creator A5065403219 @default.
• W4200322352 creator A5071868716 @default.
• W4200322352 creator A5082149678 @default.
• W4200322352 creator A5084919462 @default.
• W4200322352 creator A5087847130 @default.
• W4200322352 creator A5090182271 @default.
• W4200322352 date "2021-10-08" @default.
• W4200322352 modified "2023-09-27" @default.
• W4200322352 title "Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation" @default.
• W4200322352 cites W1516783539 @default.
• W4200322352 cites W1784175517 @default.
• W4200322352 cites W179182397 @default.
• W4200322352 cites W1847026520 @default.
• W4200322352 cites W1863488026 @default.
• W4200322352 cites W1895600627 @default.
• W4200322352 cites W1963654054 @default.
• W4200322352 cites W1968399105 @default.
• W4200322352 cites W1977149417 @default.
• W4200322352 cites W1980358129 @default.
• W4200322352 cites W1990154448 @default.
• W4200322352 cites W1992661527 @default.
• W4200322352 cites W1995391277 @default.
• W4200322352 cites W2000287607 @default.
• W4200322352 cites W2002938738 @default.
• W4200322352 cites W2012934272 @default.
• W4200322352 cites W2013945874 @default.
• W4200322352 cites W2019336592 @default.
• W4200322352 cites W2028608222 @default.
• W4200322352 cites W2030512823 @default.
• W4200322352 cites W2052685518 @default.
• W4200322352 cites W2059459105 @default.
• W4200322352 cites W2065378584 @default.
• W4200322352 cites W2068476516 @default.
• W4200322352 cites W2071682406 @default.
• W4200322352 cites W2076903503 @default.
• W4200322352 cites W2083815143 @default.
• W4200322352 cites W2085354161 @default.
• W4200322352 cites W2100184560 @default.
• W4200322352 cites W2102537088 @default.
• W4200322352 cites W2103969621 @default.
• W4200322352 cites W2107328434 @default.
• W4200322352 cites W2109042377 @default.
• W4200322352 cites W2112878705 @default.
• W4200322352 cites W2116435978 @default.
• W4200322352 cites W2120130633 @default.
• W4200322352 cites W2124101267 @default.
• W4200322352 cites W2125435699 @default.
• W4200322352 cites W2129670822 @default.
• W4200322352 cites W2133172137 @default.
• W4200322352 cites W2134683286 @default.
• W4200322352 cites W2137283681 @default.
• W4200322352 cites W2140155526 @default.
• W4200322352 cites W2141713306 @default.
• W4200322352 cites W2158961472 @default.
• W4200322352 cites W2159846640 @default.
• W4200322352 cites W2196970594 @default.
• W4200322352 cites W2288516595 @default.
• W4200322352 cites W2314203153 @default.
• W4200322352 cites W2337548499 @default.
• W4200322352 cites W2419072237 @default.
• W4200322352 cites W2512998317 @default.
• W4200322352 cites W2579916850 @default.
• W4200322352 cites W2615921597 @default.
• W4200322352 cites W2619694921 @default.
• W4200322352 cites W2754128910 @default.
• W4200322352 cites W2755158184 @default.
• W4200322352 cites W2767140416 @default.
• W4200322352 cites W2791748396 @default.
• W4200322352 cites W2795600571 @default.
• W4200322352 cites W2802130786 @default.
• W4200322352 cites W2883411530 @default.
• W4200322352 cites W2902078827 @default.
• W4200322352 cites W2917722773 @default.
• W4200322352 cites W2945618666 @default.
• W4200322352 cites W2954042561 @default.
• W4200322352 cites W2955623082 @default.
• W4200322352 cites W2959374711 @default.
• W4200322352 cites W2964249631 @default.
• W4200322352 cites W2968482725 @default.
• W4200322352 cites W2980266010 @default.
• W4200322352 cites W2983079501 @default.
• W4200322352 cites W3080748956 @default.
• W4200322352 cites W3095655536 @default.
• W4200322352 cites W3113132170 @default.
• W4200322352 cites W3139398038 @default.
• W4200322352 cites W4230312308 @default.
• W4200322352 cites W4241106625 @default.
• W4200322352 cites W4245126545 @default.
• W4200322352 cites W4245308645 @default.
• W4200322352 cites W4322697128 @default.
• W4200322352 doi "https://doi.org/10.1002/14651858.cd006466.pub7" @default.
• W4200322352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34622445" @default.
• W4200322352 hasPublicationYear "2021" @default.
• W4200322352 type Work @default.

• next